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Edited by Richard MaraisAbstract In the present study we addressed whether prolifera-
tion and apoptosis in 2-amino-1-methyl-6-phenylimidazo
[4,5-b]pyridine-induced rat mammary gland carcinomas were dif-
ferent between carcinomas with high and low expression of phos-
photyrosine (pY)-STAT5a. We determined that carcinomas with
high pY-STAT5a were more proliferative (MIB5 immunostain-
ing) and had a higher expression of cyclin D1 and estrogen recep-
tor a. Furthermore, carcinomas with elevated pY-STAT5a
demonstrated lower apoptosis as measured by the TUNEL assay
and the Bcl-2 to Bax ratio, and showed increased expression of
the long and short isoforms of the prolactin receptor. The results
of this study are consistent with the notion that activated
STAT5a may provide a growth advantage in some types of mam-
mary gland cancers.
Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Signal transducer and activator of transcription 5 (STAT5)
is a transcription factor involved in lobualveolar development,
diﬀerentiation and milk protein production in the breast that
has been implicated in breast cancer pathogenesis [1–4]. Of
the two STAT5 isoforms, STAT5a plays a more prominent
role in normal mammary gland development and diﬀerentia-
tion [2,5,6]. STAT5a is involved in cell survival in the normal
mammary gland and has been shown to regulate proliferation
of mammary alveolar epithelial cells [6,7].
Chemically-induced mammary gland cancer in the rat is a
longstanding model of human breast cancer. 2-Amino-1-
methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), a heterocyclic
amine carcinogen found in cooked meat, has been implicated
as a dietary etiological factor for human breast cancer [8,9].
We previously observed by microarray analysis that PhIP-in-
duced rat mammary gland carcinomas show increased expres-
sion of STAT5a [10]. Through immunohistochemical analysis,Abbreviations: PhIP, 2-amino-1-methyl-6-phenylimidazo[4,5-b]py-
ridine; PRLR, prolactin receptor; ERa, estrogen receptor a; pY-
STAT5a, phosphotyrosine-STAT5a
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activated STAT5a) correlated with carcinomas that were more
proliferative and poorly diﬀerentiated [11]. To further assess
the role of activated STAT5a in breast cancer, the current
study measured phosphotyrosine (pY)-STAT5a, proliferation
and apoptosis across a collection of PhIP-induced rat mam-
mary gland carcinomas. In addition, we examined the expres-
sion of the prolactin receptor (PRLR), known to aﬀect
phosphotyrosine-STAT5a (pY-STAT5a) levels through the
JAK-STAT5 pathway [12].2. Materials and methods
2.1. Animals and carcinogen treatment
Mammary carcinomas were archival samples from female Sprague–
Dawley rats treated with PhIP-HCl and placed on a high fat diet. Car-
cinomas and age-matched non-treated normal mammary glands had
been stored at80 C or formalin-ﬁxed and paraﬃn-embedded [11,13].
2.2. Immunohistochemical analysis and the TUNEL assay
Immunohistochemistry was performed using the LSAB2 system
(DakoCytomation, Carpinteria, CA) according to Shan et al. [11] with
minor modiﬁcations. The slides of 16 carcinomas classiﬁed by immu-
noprecipitation analysis to have high or low pY-STAT5a levels, and
four normal glands were incubated in duplicate with Ki-67 (1:50;
Clone MIB5; M7248) or labeled for apoptotic cells with the ApopTag
Plus Peroxidase In Situ Apoptosis Detection Kit (Chemicon Interna-
tional, Temecula, CA), according to the company’s protocol. Quanti-
tation of MIB5 stained cells and apoptotic cells were performed in
high-power (40· objective) ﬁelds for an approximate number of 1000
cells for each specimen. Measurements were performed in two sections
per specimen and an average was obtained.2.3. Immunoprecipitation analysis and immunoblotting
Mammary gland tissue was homogenized as described in Papacon-
stantinou et al. [14]. For determination of phospho-STAT5a by immu-
noprecipitation, 500 lg of total protein lysate from 21 carcinoma
samples and four normal mammary gland controls were pre-cleaned
with 0.5 lg of rabbit IgG and precipitated with 20 ll of Protein A/G
agarose (Santa Cruz). For STAT5a precipitation, 5 ll of STAT5a anti-
body (Santa Cruz, N-20) were added to the supernatant along with
20 ll of A/G agarose conjugate and the mixture was incubated on a
rocker platform overnight. The STAT5a-agarose complex was pelleted
by centrifugation at 2500 rpm for 5 min at 4 C. The pellet was washed
three times with RIPA buﬀer (50 mM Tris, 140 mM NaCl, 1%NP-40,
0.1%SDS), resuspended in loading buﬀer and denatured at 95 C. Pro-
teins were separated on 10% Tris–glycine precast gels (Invitrogen,
Carlsbad CA). The membranes were incubated with phosphotyrosine
antibody (Upstate Biotechnology clone 4G10, Lake Placid NY). The
blots were stripped and reprobed with Stat5a (N-20) antibody as an
internal control.
Immunoblotting experiments were carried out as described [14]. The
samples were the same as those used in the immunoprecipitation experi-
ment. Membranes were incubated overnight with monoclonalEuropean Biochemical Societies.
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(N–20) from Santa Cruz, estrogen receptor a (ERa) (DAKO), prolac-
tin receptor (R&D clone 218616) followed by HRP-conjugated second-
ary antibodies. Beta-actin (Sigma clone AC–15) was used as an
internal loading control.
2.4. Statistical analysis
In our immunoprecipitation experiments, pYSTAT5a levels were
normalized to the density of total STAT5a from the reprobed blot.
For the relative expression of proteins by immunoblotting, the density
of the bands was normalized to the density of the respective actin
band. The normalized ratios obtained were used to compare the nor-
mal, low pY-STAT5a and high pY-STAT5a groups using one way
ANOVA followed by the Tukey post hoc test. Each sample was run
on a gel in triplicate and signiﬁcant diﬀerence was established at a
P < 0.05. The same statistical analysis was used to compare the aver-
age percentage of stained cells obtained from staining two sections in
our immunostaining and TUNEL assay experiments.3. Results and discussion
3.1. Tumor classiﬁcation
Rat mammary gland carcinomas induced by PhIP were clas-
siﬁed into two groups based on their phosphotyrosine-STAT5a
(pY-STAT5a) levels as determined by immunoprecipitation
analysis (Fig. 1A). One group consisted of 10 carcinomas that
had pY-STAT5a protein levels similar to the normal mammary
gland. The other group consisted of 11 carcinomas showing at
least a 3-fold higher expression of pY-STAT5a (Fig. 1B).Fig. 1. Immunoprecipitation analyses for classifying PhIP-induced rat
mammary carcinomas into high and low pY-STATa groups. (A) The
ﬁgure shows a representative immunoblot of two normal (non-treated)
age-matched rat mammary glands, four carcinomas classiﬁed in the
low pY-STAT5a group and ﬁve carcinomas classiﬁed in the high pY-
STAT5a group. The blot was stripped and reprobed to measure total
STAT5a. (B) Densitometric analysis of pY-STAT5a in carcinomas
with high (N = 11) or low (N = 10) pY-STAT5a, and in normal
mammary gland (N = 4). Values shown are the means ± S.E. Letters
‘‘a’’ and ‘‘b’’ on the bars indicate statistical diﬀerences from the normal
mammary gland controls and the low pY-STAT5a groups, respectively
as determined by ANOVA and the Tukey test (P < 0.05).3.2. MIB5 immunostaining and the TUNEL assay
MIB5 antigen staining was used as an indicator of prolifer-
ating cells in rat mammary gland carcinomas. The percentage
of cells stained for MIB5 was 5.4 times higher in carcinomas
with high pY-STAT5a compared to carcinomas with low
pY-STAT5a (Fig. 2; P < 0.05). This ﬁnding is consistent with
our previous observation that carcinomas with nuclear
STAT5a have a higher PCNA nuclear labeling index [11]. In
both carcinoma groups the percentage of proliferative cells
was higher than in normal mammary gland controls
(P < 0.05). As assessed by the TUNEL assay, the percentage
of apoptotic cells in carcinomas with high pY-STAT5a was
2.8 times lower than in carcinomas with low pY-STAT5a
(Fig. 2; P < 0.05). Both carcinoma groups examined showed
higher percentage of apoptotic cells, compared to normal
mammary glands. The overall growth of the carcinomas as
estimated by the proliferation to apoptosis ratio was 10 times
higher in tumors with high pY-STAT5a (P < 0.05).3.3. Immunoblotting
Cyclin D1, a cell-cycle protein, was 3-times higher in carci-
nomas with high levels of pY-STAT5a (Fig. 3, P < 0.0.5). Pre-
vious studies have reported that STAT5a, through the Jak2/
STAT pathway, regulates the expression of cyclin D1 [6,15],
and that dominant negative STAT5 mutants are repressors
for cyclin D1 promoter activity [16,17]. Although there are
potentially several mechanisms to account for increased cyclin
D1 expression, the results of the current study raise the possi-
bility that transcriptional activation of STAT5a contributes to
elevated cyclin D1 in this tumor model.
Estrogen receptor (ER) a, a transcription factor that corre-
lates with proliferative mammary carcinomas and tends to
colocalize with cyclin D1 in our rat model [18], was 2.5 times
more abundant in carcinomas with high compared to low
pY-STAT5a (Fig. 3, P < 0.05). There was no diﬀerence be-
tween high pY-STAT5a carcinomas and normal mammary
gland. The possibility that STAT5a transcriptionally regulates
ERa expression in our tumor model requires further study.
Studies in the rat corpus luteum suggested that prolactin can
transcriptionally regulate the ERa through STAT5a [19].
The ratio of the protein levels of Bcl-2, an anti-apoptotic,
and Bax, a pro-apoptotic protein was used to estimate apopto-
sis in the carcinomas. In accordance with the TUNEL assay
data, carcinomas with high pY-STAT5a levels had more than
a 3-fold higher ratio of Bcl-2/Bax (Fig. 3). STAT5 is a survival
factor in the mammary gland [7,20], and in hematopoietic
malignancies [21–24]. Interestingly, dominant-negative forms
of STAT5 induce apoptosis in ER-positive breast cancer cells
[25].
In the mammary gland the PRLR signaling through the
Jak2-STAT5 pathway, resulting in STAT5a phosphorylation,
is essential for lobualveolar growth and the activation of genes
involved in diﬀerentiation and lactogenesis [6,26–28]. We
therefore examined the protein levels of the short and long
isoforms of the rat PRLR (Fig. 4). Prolactin receptor long
was two times higher in carcinomas with high compared to
low pY-STAT5a (P < 0.05). PRLR short was 2.4 times higher
in carcinomas with high compared to low pY-STAT5a and
was 3.3 times higher than in normal glands (P < 0.05). We pre-
viously observed an increase in prolactin receptor mRNA in
PhIP-induced mammary carcinomas via microarray analysis
Fig. 2. Immunohistochemical staining of carcinomas with low and high pY-STAT5a for the Ki-67 proliferation marker (MIB5) and the TUNEL
assay. (A) Representative images from the MIB5 staining (top row) and the TUNEL assay (bottom row). (B) Quantitation of the proliferative and
apoptotic epithelial cells. The bars represent the means ± S.E. from eight diﬀerent rat mammary glands in each group and four normal mammary
gland controls. Letters ‘‘a’’ and ‘‘b’’ on the bars indicate statistical diﬀerences from the normal mammary gland controls and the low pY-STAT5a
groups, respectively, as determined by ANOVA and the Tukey test (P < 0.05).
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the rat, the short-form of the PRLR (PRLRshort) has been
considered an inhibitor and PRLRlong an activator of the
Jak2/STAT5 pathway for diﬀerentiation and lactation [30–
33]. However, there are several reports suggesting that PRRL-
short may be mitogenic in certain cell types. For example, Das
and Vonderhaar [34] demonstrated that PRLRshort can in-
duce a mitogenic signal in NIH-3T3 cells possibly via the
MAP kinase pathway. In addition, in heterozygous PRLR+/
mice, PRRLshort was able to induce proliferation in the
mammary gland [35]. Furthermore, Russell and Richards
[36] have suggested the possibility that PRLRshort is impor-
tant for STAT5a phosphorylation and turnover. Our ﬁndings
support the possibility that elevated levels of both PRLRlongand PRLRshort facilitate proliferation in carcinomas with
high pY-STAT5a.
There are a growing number of studies concerning the
expression of Stat5 in human breast cancer [4,11,37,38]. The
results of the present study support a role for activated Stat5a
in the proliferation and survival of rat mammary gland carci-
nomas. In agreement with the ﬁndings of the present study,
Ren et al. [39] demonstrated that loss of STAT5a in breast can-
cer cells results in inhibition of tumorigenesis and an increase
in the apoptotic index. While the role speciﬁcally of STAT5a
in human breast cancer is still unclear, recent evidence suggests
that STAT5 activation distinguishes breast cancer patients
with favorable prognosis [4,40]. PhIP-induced rat mammary
gland carcinomas are not generally metastatic and have
Fig. 3. Expression of proteins involved in proliferation and apoptosis in rat mammary gland carcinomas with low and high pY-STAT5a. (A)
Representative Western blots of cyclin D1, estrogen receptor a (ERa), Bcl-2 and Bax. Actin was used as an internal loading control. (B)
Densitometric analysis of Western blots based on three measurements per specimen. Bars represent the relative expression ± S.E. of two normal
mammary gland controls, 10 low pY-STAT5a and 11 high STAT5a mammary gland carcinomas, respectively. Letters ‘‘a’’ and ‘‘b’’ on the bars
indicate statistical diﬀerences from the normal mammary gland controls and the low pY-STAT5a groups, respectively (as determined by ANOVA
and the Tukey post hoc test, P < 0.05).
Fig. 4. Expression of prolactin receptor in rat mammary gland carcinomas with low and high pY-STAT5a. (A) Representative Western blot analysis
of prolactin receptor long and short in mammary gland carcinomas with low and high pY-STAT5a expression. Actin was used as an internal loading
control. (B) Densitometric analysis of Westerns blots based on three measurements per specimen. Bar graphs represent means ± S.E. of two normal
mammary gland controls, 10 low and 11 high pY-STAT5a carcinomas. Letters ‘‘a’’ and ‘‘b’’ on the bars indicate statistical diﬀerence from the normal
mammary gland controls and the low pY-STAT5a groups, respectively (as determined by ANOVA and the Tukey post hoc test, P < 0.05).
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Further studies of Stat5a activation in the PhIP-induced ratmammary gland cancer model is expected to provide insight
into the role of Stat5a in some types of human breast cancer.
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